Actively Recruiting
68Ga-XACP3 PET/CT in Prostate Cancer
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-11-21
60
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET/CT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET/CT.
CONDITIONS
Official Title
68Ga-XACP3 PET/CT in Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with prostate cancer or highly suspected recurrence or previously treated metastases
- Scheduled for both 68Ga-PSMA PET/CT and 68Ga-XACP3 PET/CT scans
- Able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
L
Liang Zhao
CONTACT
H
Haojun Chen, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here